Skip to main content
Equibles
CRNX logo

CRNX · Crinetics Pharmaceuticals, Inc.

Track CRNX — free

Use CRNX with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about CRNX

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$84.70 +0.26 (+0.31%) At close · Aug 14
Market Cap
$8.98B
Shares
106.07M

Crinetics Pharmaceuticals, Inc. Earnings Call Transcripts

Every quarterly earnings call for Crinetics Pharmaceuticals, Inc. (CRNX) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
▲125.1% $988,000 −$50.98M '23 Q2 23-08-08 ▼100% $ −$60.10M '23 Q4 24-02-28 ▼76.1% $640,000 −$66.93M '24 Q1 24-05-09 ▼59.6% $399,000 −$74.06M '24 Q2 24-08-08 ▼100% $ −$76.83M '24 Q3 24-11-12 · $ −$80.59M '24 Q4 25-02-27 ▼43.6% $361,000 −$96.77M '25 Q1 25-05-08 ▲158.4% $1.03M −$115.64M '25 Q2 25-08-07 · $143,000 −$130.09M '25 Q3 25-11-06 · $6.16M −$122.81M '25 Q4 26-02-26 ▲2873.4% $10.73M −$127.84M '26 Q1 26-05-07 LATEST ▲2336.3% $25.12M −$120.86M '26 Q2 26-08-04
Earnings call
FY26 · Q2
2026-08-04
Webcast: Crinetics Pharmaceuticals to Report Second Quarter 2026 Financial Results
Revenue
$25.12M
▲ 2336.3% YoY
Diluted EPS
$-1.14
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q1
2026-05-07
Crinetics Pharmaceuticals, Inc. Q1 FY2026 Earnings Call
Confident tone Palsonify launch momentum Patient switching and breadth of prescribers Safety monitoring and trial conduct
Revenue
$10.73M
▲ 2873.4% YoY
Diluted EPS
$-1.23
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-02-26
Crinetics Pharmaceuticals, Inc. Q4 FY2025 Earnings Call
Confident tone PALSONIFY launch progress in acromegaly Atumelnant in CAH (Phase III) Atumelnant expansion into Cushing's disease
Revenue
$6.16M*
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-06
Crinetics Pharmaceuticals, Inc. Q3 FY2025 Earnings Call
Confident tone PALSONIFY commercial launch Atumelnant / CAH pipeline Payer access and reimbursement
Revenue
$143,000
Diluted EPS
$-1.38
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-07
Crinetics Pharmaceuticals, Inc. Q2 FY2025 Earnings Call
Confident tone PALSONIFY / paltusotine launch readiness Acromegaly market opportunity Regulatory submissions and labeling strategy
Revenue
$1.03M
▲ 158.4% YoY
Diluted EPS
$-1.23
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-08
Crinetics Pharmaceuticals, Inc. Q1 FY2025 Earnings Call
Confident tone Paltusotine commercial launch readiness Balance sheet strength and financial position CAH / atumelnant (tamelanet) Phase 3 program design
Revenue
$361,000
▼ 43.6% YoY
Diluted EPS
$-1.04
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-02-27
Crinetics Pharmaceuticals, Inc. Q4 FY2024 Earnings Call
Confident tone Paltusotine NDA acceptance and PDUFA Atumelnant in CAH and Cushing's Commercial launch readiness
Revenue
$*
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-12
Crinetics Pharmaceuticals, Inc. Q3 FY2024 Earnings Call
Confident tone Paltusotine NDA and U.S. launch preparation for acromegaly Carcinoid syndrome Phase 3 planning New NDC (non-peptide drug conjugate) oncology platform
Revenue
$
▼ 100% YoY
Diluted EPS
$-0.96
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-08
Crinetics Pharmaceuticals, Inc. Q2 FY2024 Earnings Call
Confident tone Paltusitine NDA and acromegaly Carcinoid syndrome Phase 3 planning Atumelnant Phase 2 data (CAH and Cushing's)
Revenue
$399,000
▼ 59.6% YoY
Diluted EPS
$-0.94
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-09
Crinetics Pharmaceuticals, Inc. Q1 FY2024 Earnings Call
Confident tone Atumelnant (CRN04894) clinical progress Paltusotine for acromegaly (PATHFNDR Phase III) Paltusotine for carcinoid syndrome
Revenue
$640,000
▼ 76.1% YoY
Diluted EPS
$-0.93
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-02-28
Crinetics Pharmaceuticals, Inc. Q4 FY2023 Earnings Call
Confident tone Paltusotine acromegaly program (PATHFNDR) 4894 in CAH and Cushing's disease Carcinoid syndrome program
Revenue
$*
▼ 100% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q2
2023-08-08
Crinetics Pharmaceuticals, Inc. Q2 FY2023 Earnings Call
Revenue
$988,000
▲ 125.1% YoY
Diluted EPS
$-0.94
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-03-30
Crinetics Pharmaceuticals, Inc. Q4 FY2021 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q2
2021-08-10
Crinetics Pharmaceuticals, Inc. Q2 FY2021 Earnings Call
Diluted EPS
$-0.70
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-03-30
Crinetics Pharmaceuticals, Inc. Q4 FY2020 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-11-20
Crinetics Pharmaceuticals, Inc. Q3 FY2020 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-Q
Showing 1–16 of 16 earnings calls
Key facts CIK 1658247 CUSIP 22663K107 13F (30d) 259 filings 253 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)